KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Non-Current Debt (2016 - 2025)

Eli Lilly (LLY) has disclosed Non-Current Debt for 17 consecutive years, with $40.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt rose 43.26% year-over-year to $40.9 billion, compared with a TTM value of $40.9 billion through Dec 2025, up 43.26%, and an annual FY2025 reading of $40.9 billion, up 43.26% over the prior year.
  • Non-Current Debt was $40.9 billion for Q4 2025 at Eli Lilly, roughly flat from $40.9 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $40.9 billion in Q3 2025 and bottomed at $14.1 billion in Q3 2022.
  • Average Non-Current Debt over 5 years is $22.5 billion, with a median of $18.2 billion recorded in 2023.
  • The sharpest move saw Non-Current Debt fell 8.88% in 2022, then surged 62.05% in 2024.
  • Year by year, Non-Current Debt stood at $15.3 billion in 2021, then fell by 3.97% to $14.7 billion in 2022, then rose by 24.31% to $18.3 billion in 2023, then skyrocketed by 55.71% to $28.5 billion in 2024, then soared by 43.26% to $40.9 billion in 2025.
  • Business Quant data shows Non-Current Debt for LLY at $40.9 billion in Q4 2025, $40.9 billion in Q3 2025, and $34.2 billion in Q2 2025.